Featured Jobs
|
Relationship Manager for Defined Benefits Daybright Financial
|
|
Senior ERISA Compliance Analyst Employee Fiduciary, LLC
|
|
Daybright Financial
|
|
Retirement Plan Installation & Document Manager Fringe Benefit Group
|
|
July Business Services
|
|
MAP Retirement
|
|
Defined Contribution Account Manager Nova 401(k) Associates
|
|
Relationship Manager for Defined Contributions Daybright Financial
|
|
Senior Counsel - Benefits and Total Rewards Tyson Foods
|
|
EPIC RPS
|
|
Heller Pension Associates, Inc.
|
|
Executive Assistant / Sales Support M2B Retirement Consulting LLC
|
|
Retirement Compliance Consultant Navia Benefit Solutions
|
Free Publications
|
|
GLP-1 Indications Continue to Expand: Potential Approvals Expected Through 2026
Lockton 
Aug. 27, 2025 "Wegovy has now received FDA approval for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate-to-advanced fibrosis.... The growing GLP-1 approval pipeline has significant implications for employers in terms of cost, coverage, and employee access. Throughout the end of 2026, new indications across a broad range of clinical applications are expected that employers should be aware of[.]" MORE >> |
| Please click here to report this link if it is broken (for example, if you see a "404 File Not Found" error message after you click on the linked news item's title). |
| An important word about authorship: BenefitsLink® created this link to the news item, but we are not the news item's author (unless expressly shown above). |